Posted by Michael Wonder on 31 Oct 2019
Where were the women? Gender parity in clinical trials
30 October 2019 - On October 3, the FDA approved co-formulated tenofovir alafenamide and emtricitabine (F/TAF) for HIV prevention in at-risk “adults and adolescents…excluding those who have receptive vaginal sex.”
F/TAF’s story highlights numerous flaws in the drug-approval process.
